
Pharmacally
ALS
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in ALS
Clinical TrialsPrilenia Reports Functional and Survival Signals for Pridopidine in ALSPrilenia Therapeutics and Ferrer reported exploratory functional, respiratory, and survival findings associated with pridopidine in 36 participants with early ALS.Fact-Checked
Clinical TrialsNX210c Phase 2 ALS Trial Shows Reduced Functional DeclineAxoltis Pharma reports topline Phase 2 SEALS results for NX210c in ALS. Although the primary endpoint was not met, post-hoc analyses showed slower ALSFRS-R decline versus placebo, with…Fact-Checked
ResearchNRG5051 Targets mPTP Through Novel NLRX1 Mechanism in ALSNRG Therapeutics has disclosed a novel NLRX1-mediated mechanism through which NRG5051 inhibits the mitochondrial permeability transition pore (mPTP), alongside preclinical data showing anti-inflammatory and neuroprotective effects in ALS…Fact-Checked
Clinical TrialsAB Science Discontinues Three Masitinib Trials to Prioritize ALS Phase III and AML ProgramAB Science has halted three masitinib trials in mast cell activation syndrome, mastocytosis, and multiple sclerosis, redirecting focus to ALS and AML programs.Fact-Checked
Health TidingsCoya Therapeutics Secures FDA Fast Track Tag for COYA 302 in ALSThe FDA granted Fast Track Designation to Coya Therapeutics’ investigational ALS therapy COYA 302, a biologic combination designed to enhance regulatory T cell function and reduce inflammation.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.